Search clinical trials for: Aromatase inhibitor

Total 64039 results

Pfizer

Completed

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (EUCHARIS)

Metastatic Breast Cancer

Spain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
Pfizer

Completed

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

Metastatic Breast Cancer

United States
Pfizer

Completed

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Metastatic Breast Cancer

United States
Dartmouth-Hitchcock Medical Center

Active, not recruiting

ER Reactivation Therapy for Breast Cancer (POLLY)

Metastatic Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Estrogen Receptor and/or Progesterone Receptor Positive

United States
King Faisal Specialist Hospital & Research Center

Unknown

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer

Saudi Arabia
University of Michigan

Recruiting

Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging (BETA)

Arthralgia | Aging | Breast Neoplasm Female

United States
Nemours Children's Clinic
Novartis; Pfizer; AstraZeneca; Genentech, Inc.; Thrasher Research Fund

Completed

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature (ThrasherAI)

Idiopathic Short Stature

United States, Chile
University of Wisconsin, Madison

Completed

Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?

Breast Cancer | Osteoporosis | Osteopenia | Fracture
UNICANCER
Agendia

Recruiting

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk (LESS)

Breast Cancer

France
Mridula George, MD

Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Breast Cancer

United States
American University of Beirut Medical Center

Withdrawn

Aromatase Inhibitors for Treatment of Uterine Leiomyomas

Symptomatic or Large Uterine Fibroids

Lebanon
MedImmune LLC

Completed

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer

Spain, United States, Belgium, France, United Kingdom, Canada, Israel, Germany, Hungary, Poland, Bahamas
Eli Lilly and Company

Withdrawn

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer (proMONARCH)

Metastatic Breast Cancer

United States, Taiwan, Italy, Austria, Germany, Puerto Rico, Belgium, Argentina, Brazil
Sven O. Skouby
Rigshospitalet, Denmark; Region Capital Denmark; Copenhagen University Hospital...

Completed

Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles (RIOT-B)

Infertility

Denmark
Sven O. Skouby
Zealand University Hospital; Rigshospitalet, Denmark; Hvidovre University Hospital and other collaborators

Completed

Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment (RIOT-A)

Infertility

Denmark
Centro Hospitalar Lisboa Ocidental

Unknown

HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer (HOTBreast)

Breast Cancer Female | Hormone Dependent Neoplasms

Portugal
Syndax Pharmaceuticals

Completed

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

ER+ Breast Cancer

Ireland, United Kingdom
Ain Shams University

Unknown

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT)

Metastatic Breast Cancer

Egypt
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors (PREDIX LumA)

Early-Stage Breast Carcinoma | Hormone Receptor Positive Tumor

Sweden
Pfizer

Active, not recruiting

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Metastatic Breast Cancer

United States
Korea University Anam Hospital
Korea University

Unknown

CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI) (AI-CYP19)

Breast Neoplasms | Arthritis | Arthralgia | Genetic Polymorphism

Korea, Republic of
Marina N Sharifi
Novartis; University of Wisconsin, Madison

Recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | PIK3CA Mutant Metastatic Breast Cancer

United States
Nicholas Macklon
Gedeon Richter Ltd.; Igenomix

Completed

RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2 (RIOTC)

IVF

Denmark
Alison Stopeck
Eli Lilly and Company; AstraZeneca

Withdrawn

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Locally Advanced Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Withdrawn

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Breast Cancer
Eli Lilly and Company

Completed

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

India
Mỹ Đức Hospital

Completed

Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study

Poor Ovarian Response

Vietnam
Novartis Pharmaceuticals
GlaxoSmithKline

Completed

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Neoplasms, Breast

Belgium, United Kingdom, Croatia, Hungary, Argentina, Australia, Germany, Israel, Japan, Poland, Russian Federation, Spain, France, Korea, Republic of, Hong Kong, United States, Brazil, Bulgaria, China, India, Ireland, Italy, Philip... and more
NHS Tayside

Completed

Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers (BARONET)

Breast Cancer

United Kingdom
Xichun Hu

Completed

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

Metastatic Breast Cancer

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Breast Cancer

United States, Puerto Rico
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States, Canada
Prof. Wolfgang Janni
Eli Lilly and Company

Recruiting

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA)

Hormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast Cancer

Germany, Switzerland
Second Affiliated Hospital, School of Medicine,...
GeneCast Biotechnology Co., Ltd.

Recruiting

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Luminal B/HER2-negative Breast Cancer

China
Consorzio Oncotech

Unknown

Overcoming Endocrine Resistance in Metastatic Breast Cancer (OVER)

Metastatic Breast Cancer

Italy
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC (CAPACITY)

Hormone Receptor Positive Advanced Breast Cancer

China
Vanderbilt University Medical Center
American Cancer Society, Inc.; National Center for Research Resources (NCRR)

Completed

Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors

Breast Cancer | Arthralgia

United States
International Cancer Research Group, United Arab...
King Saud University Medical City, Riyadh, Saudi Arabia; Max-Planck-Institut... and other collaborators

Recruiting

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (ICRG0201)

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

Algeria, Jordan, Saudi Arabia
British Columbia Cancer Agency
Janssen Research & Development, LLC

Withdrawn

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

Canada
Nik Hazlina

Completed

The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)

Polycystic Ovarian Syndrome
Rigshospitalet, Denmark

Completed

Short-Term Androgen Priming Before COS Using Aromatase Inhibitor and hCG During Early-Follicular-Phase GnRH Antagonist Administration - a Randomized Controlled Trial

Infertility

Denmark
Monica Mita
Cedars-Sinai Medical Center

Terminated

NEOBREADS: Neoadjuvant Breast Diet Study (NEOBREADS)

Breast Cancer

United States
Pfizer

Completed

Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy (TAMARA)

Breast Neoplasms

Turkey
Tvardi Therapeutics, Incorporated

Active, not recruiting

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Breast Cancer

United States
Pfizer

Completed

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Breast Neoplasms

Qatar, United Arab Emirates, Saudi Arabia
Minia University

Completed

Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI (AIPRICSI)

Infertility Indicated for ICSI

Egypt
Farin Amersi

Terminated

BREADS: Breast Adjuvant Diet Study

Breast Cancer

United States
Robert H. Lurie Cancer Center
National Cancer Institute (NCI)

Withdrawn

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
Pfizer

Active, not recruiting

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Breast Cancer

United States

3

Subscribe